Organization
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
18 clinical trials
Clinical trial
Single-arm, Open-label, Multicenter Phase Ib Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade SarcomaStatus: Terminated, Estimated PCD: 2023-06-28
Clinical trial
A Phase III Clinical Study Evaluating the Efficacy and Safety of On-demand Treatment and Perioperative Replacement Therapy With Recombinant Human Coagulation Factor VIII for Injection in Treated Severe Hemophilia AStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy VolunteersStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase I Clinical Study of TQB2922 for Injection in Patients With Advanced CancersStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult SubjectsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials to Assess the Effectiveness, Safety and Pharmacokinetics of TQH2722 Injection in Patients With Chronic Sinusitis With or Without Nasal Polyps.Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I Study of TQB2102 Injection in Patients With Advanced CancersStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate AP026 (TQA2226) for Injection in Adult Subjects After Single/Multiple Administration.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase I Clinical Trial to Evaluate the Tolerability and Safety of TQB2858 Injection in Subjects With Metastatic Pancreatic CancerStatus: Terminated, Estimated PCD: 2023-11-27
Clinical trial
A Phase I Clinical Trial Evaluating Tolerance, Safety, Pharmacokinetics, and Initial Effectiveness of TQB2103 for Injection in Patients With Advanced Cancers.Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase Ib/II Clinical Trial of TQB3909 Tablets in Subjects With Relapsed or Refractory MCL Safety and EfficacyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Clinical Trial of TQB2102 for Injection in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) -Expressing Relapsed/Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
The Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection in Human Epidermal Growth Factor Receptor 2 (HER2) Negative Recurrent/Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Multicenter, Randomized, Ongoing Trial Evaluating the Long-term Safety and Efficacy of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal PolypsStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects and Psoriasis SubjectsStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of TQB2102 for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract CancerStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TQC2938 Injection in Healthy Adult Subjects After Single and Multiple AdministrationStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Multicenter, Open-label, Multi-cohort Phase Ib Trial Evaluating the Efficacy and Safety of TQB2928 Injection Combined With Anlotinib Hydrochloride Capsule in Relapsed/Metastatic Osteosarcoma and Other Relapsed/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-01